纤维细胞生长因子受体表达在血管母细胞瘤:一个新的治疗点
Maya Puttonen1, Olli Tynninen2, Sami Salmikangas1
1Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
PloS one
|May 20, 2025
概括
纤维细胞生长因子受体 (FGFRs) 存在于血管母细胞瘤中,这是一种脑瘤. FGFR2和FGFR4的表达表明它们是这种疾病的潜在治疗点.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 血管母细胞瘤是血管性中枢神经系统瘤,通常与·希佩尔-林道氏病 (VHL) 相关.
- 目前的手术等治疗方法并不总是完全有效,这凸显了针对性治疗的必要性.
- 纤维细胞生长因子受体 (FGFRs) 参与瘤生长和血管生成,使其成为潜在的治疗点.
研究的目的:
- 研究FGFR家族成员在血液血管母细胞瘤中的表达和重要性.
- 确定FGFR表达是否与VHL疾病状态,患者人口统计学或瘤特征相关.
主要方法:
- 使用免疫组织化学分析了139个血管母细胞瘤样本.
- 评估FGFR1,FGFR2,FGFR3和FGFR4表达的情况.
- FGFR表达与VHL突变状态,患者的性别,瘤位置和瘤大小的相关性.
主要成果:
- 在血液血管母细胞瘤中观察到FGFR2 (95%) 和FGFR4 (61%) 的高表达.
- 在VHL突变瘤和男性患者中,FGFR2表达升高.
- 在位于大脑的瘤中,FGFR4表达更常见,并且与较大的瘤直径有关.
结论:
- 在血管母细胞瘤中,FGFR2和FGFR4的显著表达.
- 这些发现表明,FGFRs代表了对血管母细胞瘤治疗的有前途的治疗点.
- 向FGFRs可能为血液血管母细胞瘤患者的个性化治疗提供新的途径.
更多相关视频
12:09A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013
11.4K
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
7.6K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Introduction to Fibroblasts
3.0K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
